Medical News Home

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that New Zealand Health Minister, the Honorable David Cunliffe, has approved an application from the company to conduct in New Zealand a Phase I/IIa clinical trial of DiabeCell®, LCT’s lead product candidate for the treatment of insulin dependent (Type 1) diabetes.

GPs and GP registrars now have access to a new Clinical e-Audit developed by National Prescribing Service Limited (NPS), which can assist with the management of patients with type 2 diabetes.

Johns Hopkins scientists were dubious in the early 1980s when they stumbled on small sugar molecules lurking in the centers of cells; not only were they not supposed to be there, but they certainly weren’t supposed to be repeatedly attaching to and detaching from proteins, effectively switching them on and off.

Health Minister (Wales) Edwina Hart has today unveiled new guidelines that form part of a delivery strategy for the management of adults with diabetes in Wales. Almost 5% of the population in Wales are known to have diabetes and it is estimated there are about 50,000 people with diabetes who remain undiagnosed.

Leading health charity Diabetes UK warns that the number of people diagnosed with diabetes in the UK has risen by more than 167,000 since last year, bringing the total diabetes population to almost 2.5 million according to new data¹ from GP practices. This rise is more than double the 2006 to 2007 increase of 83,000. In England, a 6.

A respected Queensland University of Technology researcher and his team have received $5 million from the Juvenile Diabetes Foundation International, the third-biggest grant they have ever given to an Australian research team.

Xingxing Zang, Ph.D., Assistant Professor of the Microbiology and Immunology Department at Albert Einstein College of Medicine, has been awarded a five-year, $1.5 million NIH grant to study novel molecular approaches to treat type 1 diabetes (T1D). Dr.

A molecule called interleukin-6 has opened new doors for the creation of new drugs against obesity and diabetes. These are the conclusions of an international project which has had the participation of researchers from Vitagenes, a company which forms part of the Campus program promoted by the University of Granada (UGR) and situated in the Technological Park of Health Sciences (PTS).

A new study by researchers in Scotland suggests that while there is evidence of benefit to non-diabetics with no history of heart disease or stroke, people with diabetes should not take aspirin to prevent heart disease and stroke unless they already have a history of these complaints.

Today, at the Canadian Diabetes Association Congress, physicians will get a first-time look at more detailed results from a phase 3b clinical study (LEAD™ 6) comparing the investigational new drug liraglutide to exenatide.